- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01856361
Ramipril for the Treatment of Oligospermia
April 27, 2017 updated by: Weill Medical College of Cornell University
Ramipril for the Treatment of Oligospermia: A Double-Blind Randomized Control Trial
This is a randomized controlled trial to evaluate the effect of ramipril in stimulating and promoting sperm production in men with low sperm count.
Ramipril is an Angiotensin Converting Enzyme Inhibitor (ACEI) currently used to treat high blood pressure.
However, previous studies have shown that this class of medications can improve sperm parameters.
The purpose of this study is to evaluate the efficacy of ramipril compared to placebo (Substance That is not known to have treatment effect), in improving sperm density in infertile men with documented low sperm count.
This study will help us identify subjects that might benefit from treatment with this medication, and the effect it will have on sperm count, shape, and motility.
Study Overview
Status
Terminated
Intervention / Treatment
Detailed Description
Approximately half of all infertility problems are caused by male factors.
These men account for 17% of patients at the primary health care level that seek help for infertility.
Oligospermia (Low sperm count) of unknown cause occurs in up to 60% of men with unexplained infertility.
Certain group of patients with oligospermia can father children, but those with infertility have long posed a major therapeutic challenge.
A variety of empirical non-specific treatments have been used, in attempt to improve their semen characteristics and fertility.
In the past, androgens were suggested as a treatment; however, exogenous testosterone was found to exert negative feedback on the pituitary-gonadal axis and thereby suppresses Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) secretion then adversely affects sperm production.
Other treatment modalities like clomiphene citrate, tamoxifen, recombinant FSH, zinc, selenium, and L-carnitine have been tried with minimal success.
In the present study we are proposing the use of an angiotensin converting enzyme inhibitor (ACEI) for the treatment of oligospermia.
A recently published pilot study showed that the use of lisinopril improved sperm quantity and quality in oligospermic men.
ACEI are inexpensive, safe, widely available, and, if effective in improving sperm production and quality, could avert couples from undergoing invasive procedures.
Study Type
Interventional
Enrollment (Actual)
2
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Weill Cornell Medical College, Department of Urology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Male partner of a couple presenting for infertility.
- Moderate abnormalities of semen parameters (Mean sperm density <20 million, but ≥ 3 million/ml), and/or motility < 50%, and/or < 4% abnormal morphology on at least two separate occasions.
- Age 18-45 years.
- Normal renal function defined as Glomerular filtration rate > 90
Exclusion Criteria:
- Patients that are currently taking thiazide, cyclosporin, lithium, and allopurinol or the use of these medications in the last 2 weeks.
- The frequent use of NSAIDS (3 or more times a week).
- Vasectomy reversal.
- Regular use of tobacco products.
- Mean white blood cell count >1 million/ml in the ejaculate.
- Inability or unwillingness to participate in evaluations required by the study.
- Potassium > 5.0.
- Systolic blood pressure < 90 mmHg.
- Currently use of ACEI
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ramipril
The initial dose of ramipril will be 2.5 mg that will be started at visit 2, week zero of the study.
The dose will be increased to 5 mg during visit 3, 4 weeks into the study, for a total of 32 weeks.
|
Angiotensin Converting Enzyme Inhibitor
Other Names:
|
Sham Comparator: Placebo
The placebo group will get a similar pill that will be started at visit 2, week zero of the study.
Subjects will be asked to double the dose by taking two pills during visit 3, four weeks into the study, for a total of 32 weeks.
|
Placebo pill that will match the treatment pill
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Sperm Density in Infertile Men With Documented Oligospermia.
Time Frame: 32 weeks
|
32 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Motile Sperm Count(TMSC), Total Sperm Count, Sperm Motility, and Morphology in the Ejaculate.
Time Frame: 32 weeks
|
The efficacy of ramipril in improving total sperm count will be evaluated, as well as, improving sperm motility, and morphology.
|
32 weeks
|
Pregnancy Rate
Time Frame: 32 weeks
|
32 weeks
|
|
Hormonal Profile
Time Frame: 32 weeks
|
LH, FSH, serum testosterone, prolactin
|
32 weeks
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Seminal Angiotensin II and Serum Bradykinin Levels
Time Frame: 32 weeks
|
32 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Peter N Schlegel, MD, Weill Medical College of Cornell University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2013
Primary Completion (Actual)
June 1, 2016
Study Completion (Actual)
June 1, 2016
Study Registration Dates
First Submitted
May 9, 2013
First Submitted That Met QC Criteria
May 16, 2013
First Posted (Estimate)
May 17, 2013
Study Record Updates
Last Update Posted (Actual)
June 2, 2017
Last Update Submitted That Met QC Criteria
April 27, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1301013462
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Male Infertility
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Jinling Hospital, ChinaRecruitingMale Infertility Due to HypospermatogenesisChina
-
Reproductive Medicine Associates of New JerseyTerminated
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Sapientiae InstituteTerminated
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
Hillel Yaffe Medical CenterUnknownMale Infertility With Severe Oligo-terato-asteno-spermiaIsrael
-
Universitair Ziekenhuis BrusselRecruitingMale InfertilityBelgium
-
Istituto Clinico HumanitasRecruiting
Clinical Trials on Ramipril
-
Novartis PharmaceuticalsCompletedHeart FailureRussian Federation, Germany, Poland
-
Boehringer IngelheimCompleted
-
SandozCompleted
-
Gulhane School of MedicineCompletedDiabetes | Proteinuria | Renin Angiotensin SystemTurkey
-
SandozCompleted
-
SanofiCompleted
-
Ranbaxy Laboratories LimitedCompleted
-
Institut de Recherches Cliniques de MontrealTerminatedHypertension | Type 2 Diabetes | AlbuminuriaCanada
-
PfizerTerminatedHypertensionUnited States, Argentina, Colombia, India, Chile, Poland, South Africa, Turkey, Ukraine